Physician profile
Anne D Tweedy
NPI 1659395531
$2,883.23
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $813 · 2022: $928 · 2023: $724 · 2024: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984 · Education: $140 · Debt Forgiveness: $17.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.33 |
| Education | $139.94 |
| Debt Forgiveness | $17.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $485.67 | 2021-2024 | |
| Novo Nordisk INC | $361.28 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $349.79 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.14 | 2021-2023 | Jardiance |
| Astellas Pharma US INC | $192.49 | 2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $187.36 | 2022 | |
| Janssen Pharmaceuticals, INC | $177.24 | 2021-2022 | |
| Glaxosmithkline, LLC. | $161.64 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.01 | 2021-2022 | |
| Lilly USA, LLC | $94.62 | 2021-2023 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $75.32 | 2021-2023 | Rexulti |
| Pfizer INC. | $68.85 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.06 | 2021 | |
| Vanda Pharmaceuticals INC. | $48.44 | 2023 | Hetlioz |
| Exact Sciences Corporation | $41.92 | 2023 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $35.65 | 2023 | Yupelri |
| Neurocrine Biosciences, INC. | $25.22 | 2023 | Ingrezza |
| Xeris Pharmaceuticals, INC. | $24.38 | 2024 | Gvoke Hypopen |
| Baxter Healthcare | $17.74 | 2024 | |
| Merck Sharp & Dohme LLC | $17.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.88 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.56 | 2021 | |
| Sanofi Pasteur INC. | $13.56 | 2021 | |
| Hologic Sales and Service, LLC | $12.22 | 2021 | |
| Amgen INC. | $11.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Tweedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.